Big Profits on Stop-Smoking Research: Top Performer Report

691685071 = Sergey Molchenko|||

Stocks are registering a mixed performance today, with most major indexes down or flat at the time of this writing. Traders may simply be taking a step back after a red-hot start to the trading year. News of the Trump administration’s plans for a series of protectionist tariffs likely played some role, however.

Today’s Top Performer comes from one our most dependable sources of same-day news-based trading gains over the past year: the pharmaceutical sector. A single announcement—on anything from a patent to a clinical trial—can rapidly change investor outlook on a stock in a way that’s largely unique to this industry. As today’s Top Performer shows, simply agreeing to cooperate on research with a respected institution can cause investors to reevaluate an equity’s potential future earnings.

Achieve Life Sciences (ACHV): Dramatic gains on announcement of new

research agreement.

This morning, Achieve Life Sciences announced a new research agreement with the University of Bristol, located in the United Kingdom. They have been in an agreement with Bristol since last June, but its terms received substantial amendment, released today. Under the old agreement, ACHV held rights only to treatments related to smoking cessation; the new agreement covers broader potential applications.

ACHV is a clinical drug development company focused on applications of their cytisine treatment in smoking cessation.

ACHV will hold all rights to human-use treatments developed under the new research facility, which will focus on testing the potential of various derivatives of cytisine. In addition to smoking cessation, they are evaluating these compounds for potential use in treating other addictions, and even broader neurological disorders.

Investors bought the stock on heavy volume following the announcement, driving it to gains over 50% at the time of this writing (a consolidation from an initial rally over 100%). This astonishing rally seems to be a case of investors “reading between the lines” –ACHV wouldn’t have bothered with this agreement revision, they’re betting, if they weren’t seeing broader potential applications for cytisine emerging during research.

Diverse Plays, Great Profits: All in a single news day.

Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!

We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.

Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock

A powerful news analytics platform like News Quantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.

How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like News Quantified?  Let us know in the comments below.

Leave a comment